CORDIS
EU research results

CORDIS

English EN

An innovative topical drug delivery system for improving chronic wound healing

Project information

Grant agreement ID: 885973

Status

Ongoing project

  • Start date

    1 November 2019

  • End date

    29 February 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

STRATPHARMA AG

Switzerland

Objective

Skin is the largest organ in the human body, forming a protective physical barrier against the outside world. Damages to skin due to physical, chemical and biological factors lead to wounds. While minor wounds heal on their own, chronic wounds (wounds that do not heal within 8 weeks), such as diabetic foot ulcers, subject the patient to significant discomfort and distress while draining the medical system of an enormous amount of resources. Wound healing is a complex, highly regulated process, and complications affect the quality of life of >4 million a year in EU (more than cancer & diabetes) that struggle to live with hard-to-heal injuries, as it can lead to infection, tissue and bone necrosis, pain and in some severe cases even amputation. Stratpharma has developed a range of primary dressings formulated as a silicone-based gel, which can be used on any wounded, damaged, compromised or diseased skin surface. This proprietary film-forming gel is also shown to be an excellent drug delivery system, using which active compounds can be delivered to the wound, thereby enhancing clinical outcomes. Using this property, Stratpharma aims to develop a breakthrough formulation, containing gel and bioglass technology, for improved chronic wound healing. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, Stratpharma will further test and validate the new formulation, begin clinical trials, implement IP strategy and perform scaling-up activities.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STRATPHARMA AG

Address

Aeschenvorstadt 57
4051 Basel

Switzerland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 885973

Status

Ongoing project

  • Start date

    1 November 2019

  • End date

    29 February 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

STRATPHARMA AG

Switzerland